Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Webcasts


Play ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a)
Gregory G. Schwartz Michael Szarek ODYSSEY OUTCOMES: Recurrent events, mortality and Lp(a)
Play Lp(a) and CV risk: Insights from the FOURIER trial
Erin Bohula Lp(a) and CV risk: Insights from the FOURIER trial
Play Genetics of Lp(a) and CVD
Anne Tybjaerg-Hansen Genetics of Lp(a) and CVD
Play Do LDL subfractions matter?
John Chapman Do LDL subfractions matter?
Play PCSK9 and the adrenals: how are cholesterol levels protected?
Bo Angelin PCSK9 and the adrenals: how are cholesterol levels protected?
Play Does one plaque characteristic fit all?
Gerard Pasterkamp Does one plaque characteristic fit all?
Play Lp(a) as a cardiovascular risk factor – Is lowering Lp(a) beneficial when LDL is low?
Pia Kamstrup Lp(a) as a cardiovascular risk factor – Is lowering Lp(a) beneficial when LDL is low?
Play Low LDL-C and cognitive function: Benefit or harm?
Francois Mach Low LDL-C and cognitive function: Benefit or harm?
Play Do low LDL-C levels enhance diabetes risk?
Dirk Müller-Wieland Do low LDL-C levels enhance diabetes risk?
Play Do low LDL-C levels achieved with statin therapy increase the risk for diabetes mellitus?
Henry Ginsberg Do low LDL-C levels achieved with statin therapy increase the risk for diabetes mellitus?
Play ODESSEY OUTCOMES Trial: Topline results
J Wouter Jukema ODESSEY OUTCOMES Trial: Topline results
Play Inclisiran and the ORION Project
Frederick J. Raal Inclisiran and the ORION Project
Play FOURIER: Timing is everything
Gaetano De Ferrari FOURIER: Timing is everything
Play An update on inclisiran
Kausik Ray An update on inclisiran
Play An update on cardiovascular disease, depression and adherence
David Hare An update on cardiovascular disease, depression and adherence
Play A background to siRNA: Pushkal Garg, Alnylam
Pushkal Garg A background to siRNA: Pushkal Garg, Alnylam
Play How do we identify very high risk patients for PCSK9 inhibition? Part Two
Ulf Landmesser How do we identify very high risk patients for PCSK9 inhibition? Part Two
Play How do we identify very high risk patients for PCSK9 inhibition? Part One
Erik Stroes How do we identify very high risk patients for PCSK9 inhibition? Part One
Play Profiling patients with ACS: What are the prospects for PCSK9 inhibition?
Gregory G. Schwartz Profiling patients with ACS: What are the prospects for PCSK9 inhibition?
Play PCSK9 and the beta-cell
Bertrand Cariou PCSK9 and the beta-cell